Drew Moghanaki: The Role of Preoperative SBRT for NSCLC
Drew Moghanaki, Chief Medical Officer at Respirati, shared a post on X about recent article Nasser Altorki and colleagues authored:
“Nasser Altorki‘s team publishes new data investigating the role of preop SBRT for NSCLC. This time, reporting their institutional data comparing preop SBRT-IO vs Chemo-IO. The results demonstrate a significant association with improved RFS at 2 years with SBRT delivered BEFORE immunotherapy (92% vs 64%, HR = 0.19). Technique = 8 Gy x 3, omiting the LNs.”
Title: Neoadjuvant Non-Ablative SBRT Plus Immunotherapy Yields Similar Pathologic Response as Chemo-Immunotherapy in Non-Small Cell Lung Cancer
Authors: Dan Jones, Abu Nasar, Jonathan Villena-Vargas, Sebron Harrison, Oliver Chow, Muhammad Ali, Eugene Shostak, Ashish Saxena, Christine Garcia, Giuseppe Giaccone, Nicholas J. Sanfilippo, Silvia Formenti, Benjamin Lee, Jeffrey L. Port, Nasser Altorki
More posts featuring Drew Moghanaki on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023